[{"orgOrder":0,"company":"Nemysis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Iron Hydroxide Adipate Tartrate","moa":"Iron","graph1":"Hematology","graph2":"Phase II","graph3":"Nemysis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nemysis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nemysis \/ Not Applicable"},{"orgOrder":0,"company":"Nemysis","sponsor":"Bruno Farmaceutici","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Iron Hydroxide Adipate Tartrate","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Nemysis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nemysis \/ Bruno Farmaceutici","highestDevelopmentStatusID":"12","companyTruncated":"Nemysis \/ Bruno Farmaceutici"},{"orgOrder":0,"company":"Kolinpharma","sponsor":"Nemysis","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Iron Hydroxide Adipate Tartrate","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Kolinpharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kolinpharma \/ Nemysis","highestDevelopmentStatusID":"12","companyTruncated":"Kolinpharma \/ Nemysis"}]

Find Clinical Drug Pipeline Developments & Deals for Iron Hydroxide Adipate Tartrate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BOS Manchester
                          Not Confirmed
                          BOS Manchester
                          Not Confirmed

                          Details : Kolinpharma will market Iron Hydroxide Adipate Tartrate (IHAT), an oral iron supplement for iron deficiency, utilizing its existing sales network under the brand KIPFeR.

                          Brand Name : KIPFeR

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 10, 2024

                          Lead Product(s) : Iron Hydroxide Adipate Tartrate

                          Therapeutic Area : Hematology

                          Highest Development Status : Approved

                          Sponsor : Nemysis

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          BOS Manchester
                          Not Confirmed
                          BOS Manchester
                          Not Confirmed

                          Details : Under the agreement, Bruno will use its existing sales network and relationships with relevant clinical communities to market IHAT (iron hydroxide adipate tartrate), an oral iron supplementation product, under its own brand.

                          Brand Name : IHAT

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 05, 2023

                          Lead Product(s) : Iron Hydroxide Adipate Tartrate

                          Therapeutic Area : Hematology

                          Highest Development Status : Approved

                          Sponsor : Bruno Farmaceutici

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The patent claims describe methods for producing IHAT (Iron Hydroxide Adipate Tartrate), where Generally Recognised As Safe (GRAS) organic acids, and particularly Tartaric and Adipic acids, are used to modify the ferrihydrite nanocore of ferritin.

                          Brand Name : IHAT-02

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 12, 2021

                          Lead Product(s) : Iron Hydroxide Adipate Tartrate

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank